China Plasma-derived Therapies Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • This report offers an overview of the market trends, drivers, and barriers with respect to the China Plasma-derived Therapies market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Plasma-derived Therapies market. Detailed analysis of key players, along with key growth strategies adopted by Plasma-derived Therapies industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Kedrion

    • Grifols

    • Octaparma

    • CSL Behring LLC

    • Takeda

    • Bayer

    • Shire

    • LFB

    • Bio Products Laboratory (BPL)

    • Biotest

    By Type:

    • Albumin

    • Immunoglobulin

    • Factor VIII

    • Others

    By End-User:

    • Hemophilia

    • Primary Immunodeficiencies (PIDs)

    • Idiopathic Thrombocytopenic Purpura (ITP)

    • COVID-19

    • Others

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Plasma-derived Therapies Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Plasma-derived Therapies Market Size and Growth Rate of Albumin from 2016 to 2027

    • 1.3.2 China Plasma-derived Therapies Market Size and Growth Rate of Immunoglobulin from 2016 to 2027

    • 1.3.3 China Plasma-derived Therapies Market Size and Growth Rate of Factor VIII from 2016 to 2027

    • 1.3.4 China Plasma-derived Therapies Market Size and Growth Rate of Others from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Plasma-derived Therapies Market Size and Growth Rate of Hemophilia from 2016 to 2027

    • 1.4.2 China Plasma-derived Therapies Market Size and Growth Rate of Primary Immunodeficiencies (PIDs) from 2016 to 2027

    • 1.4.3 China Plasma-derived Therapies Market Size and Growth Rate of Idiopathic Thrombocytopenic Purpura (ITP) from 2016 to 2027

    • 1.4.4 China Plasma-derived Therapies Market Size and Growth Rate of COVID-19 from 2016 to 2027

    • 1.4.5 China Plasma-derived Therapies Market Size and Growth Rate of Others from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Plasma-derived Therapies Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Plasma-derived Therapies by Major Types

    • 3.4.1 Market Size and Growth Rate of Albumin

    • 3.4.2 Market Size and Growth Rate of Immunoglobulin

    • 3.4.3 Market Size and Growth Rate of Factor VIII

    • 3.4.4 Market Size and Growth Rate of Others

    4 Segmentation of Plasma-derived Therapies Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Plasma-derived Therapies by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Plasma-derived Therapies in Hemophilia

    • 4.4.2 Market Size and Growth Rate of Plasma-derived Therapies in Primary Immunodeficiencies (PIDs)

    • 4.4.3 Market Size and Growth Rate of Plasma-derived Therapies in Idiopathic Thrombocytopenic Purpura (ITP)

    • 4.4.4 Market Size and Growth Rate of Plasma-derived Therapies in COVID-19

    • 4.4.5 Market Size and Growth Rate of Plasma-derived Therapies in Others

    5 Market Analysis by Regions

    • 5.1 China Plasma-derived Therapies Production Analysis by Regions

    • 5.2 China Plasma-derived Therapies Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Plasma-derived Therapies Landscape Analysis

    • 6.1 North China Plasma-derived Therapies Landscape Analysis by Major Types

    • 6.2 North China Plasma-derived Therapies Landscape Analysis by Major End-Users

    7 Central China Plasma-derived Therapies Landscape Analysis

    • 7.1 Central China Plasma-derived Therapies Landscape Analysis by Major Types

    • 7.2 Central China Plasma-derived Therapies Landscape Analysis by Major End-Users

    8 South China Plasma-derived Therapies Landscape Analysis

    • 8.1 South China Plasma-derived Therapies Landscape Analysis by Major Types

    • 8.2 South China Plasma-derived Therapies Landscape Analysis by Major End-Users

    9 East China Plasma-derived Therapies Landscape Analysis

    • 9.1 East China Plasma-derived Therapies Landscape Analysis by Major Types

    • 9.2 East China Plasma-derived Therapies Landscape Analysis by Major End-Users

    10 Northeast China Plasma-derived Therapies Landscape Analysis

    • 10.1 Northeast China Plasma-derived Therapies Landscape Analysis by Major Types

    • 10.2 Northeast China Plasma-derived Therapies Landscape Analysis by Major End-Users

    11 Southwest China Plasma-derived Therapies Landscape Analysis

    • 11.1 Southwest China Plasma-derived Therapies Landscape Analysis by Major Types

    • 11.2 Southwest China Plasma-derived Therapies Landscape Analysis by Major End-Users

    12 Northwest China Plasma-derived Therapies Landscape Analysis

    • 12.1 Northwest China Plasma-derived Therapies Landscape Analysis by Major Types

    • 12.2 Northwest China Plasma-derived Therapies Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 Kedrion

      • 13.1.1 Kedrion Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 Grifols

      • 13.2.1 Grifols Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    • 13.3 Octaparma

      • 13.3.1 Octaparma Company Profile and Recent Development

      • 13.3.2 Market Performance

      • 13.3.3 Product and Service Introduction

    • 13.4 CSL Behring LLC

      • 13.4.1 CSL Behring LLC Company Profile and Recent Development

      • 13.4.2 Market Performance

      • 13.4.3 Product and Service Introduction

    • 13.5 Takeda

      • 13.5.1 Takeda Company Profile and Recent Development

      • 13.5.2 Market Performance

      • 13.5.3 Product and Service Introduction

    • 13.6 Bayer

      • 13.6.1 Bayer Company Profile and Recent Development

      • 13.6.2 Market Performance

      • 13.6.3 Product and Service Introduction

    • 13.7 Shire

      • 13.7.1 Shire Company Profile and Recent Development

      • 13.7.2 Market Performance

      • 13.7.3 Product and Service Introduction

    • 13.8 LFB

      • 13.8.1 LFB Company Profile and Recent Development

      • 13.8.2 Market Performance

      • 13.8.3 Product and Service Introduction

    • 13.9 Bio Products Laboratory (BPL)

      • 13.9.1 Bio Products Laboratory (BPL) Company Profile and Recent Development

      • 13.9.2 Market Performance

      • 13.9.3 Product and Service Introduction

    • 13.10 Biotest

      • 13.10.1 Biotest Company Profile and Recent Development

      • 13.10.2 Market Performance

      • 13.10.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Albumin from 2016 to 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Immunoglobulin from 2016 to 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Factor VIII from 2016 to 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Others from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Hemophilia from 2016 to 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Primary Immunodeficiencies (PIDs) from 2016 to 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Idiopathic Thrombocytopenic Purpura (ITP) from 2016 to 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of COVID-19 from 2016 to 2027

    • Figure China Plasma-derived Therapies Market Size and Growth Rate of Others from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Plasma-derived Therapies Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Plasma-derived Therapies Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Plasma-derived Therapies

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Plasma-derived Therapies by Different Types from 2016 to 2027

    • Table Consumption Share of Plasma-derived Therapies by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Albumin

    • Figure Market Size and Growth Rate of Immunoglobulin

    • Figure Market Size and Growth Rate of Factor VIII

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Plasma-derived Therapies by Different End-Users from 2016 to 2027

    • Table Consumption Share of Plasma-derived Therapies by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Hemophilia

    • Figure Market Size and Growth Rate of Primary Immunodeficiencies (PIDs)

    • Figure Market Size and Growth Rate of Idiopathic Thrombocytopenic Purpura (ITP)

    • Figure Market Size and Growth Rate of COVID-19

    • Figure Market Size and Growth Rate of Others

    • Table China Plasma-derived Therapies Production by Regions

    • Table China Plasma-derived Therapies Production Share by Regions

    • Figure China Plasma-derived Therapies Production Share by Regions in 2016

    • Figure China Plasma-derived Therapies Production Share by Regions in 2021

    • Figure China Plasma-derived Therapies Production Share by Regions in 2027

    • Table China Plasma-derived Therapies Consumption by Regions

    • Table China Plasma-derived Therapies Consumption Share by Regions

    • Figure China Plasma-derived Therapies Consumption Share by Regions in 2016

    • Figure China Plasma-derived Therapies Consumption Share by Regions in 2021

    • Figure China Plasma-derived Therapies Consumption Share by Regions in 2027

    • Table North China Plasma-derived Therapies Consumption by Types from 2016 to 2027

    • Table North China Plasma-derived Therapies Consumption Share by Types from 2016 to 2027

    • Figure North China Plasma-derived Therapies Consumption Share by Types in 2016

    • Figure North China Plasma-derived Therapies Consumption Share by Types in 2021

    • Figure North China Plasma-derived Therapies Consumption Share by Types in 2027

    • Table North China Plasma-derived Therapies Consumption by End-Users from 2016 to 2027

    • Table North China Plasma-derived Therapies Consumption Share by End-Users from 2016 to 2027

    • Figure North China Plasma-derived Therapies Consumption Share by End-Users in 2016

    • Figure North China Plasma-derived Therapies Consumption Share by End-Users in 2021

    • Figure North China Plasma-derived Therapies Consumption Share by End-Users in 2027

    • Table Central China Plasma-derived Therapies Consumption by Types from 2016 to 2027

    • Table Central China Plasma-derived Therapies Consumption Share by Types from 2016 to 2027

    • Figure Central China Plasma-derived Therapies Consumption Share by Types in 2016

    • Figure Central China Plasma-derived Therapies Consumption Share by Types in 2021

    • Figure Central China Plasma-derived Therapies Consumption Share by Types in 2027

    • Table Central China Plasma-derived Therapies Consumption by End-Users from 2016 to 2027

    • Table Central China Plasma-derived Therapies Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Plasma-derived Therapies Consumption Share by End-Users in 2016

    • Figure Central China Plasma-derived Therapies Consumption Share by End-Users in 2021

    • Figure Central China Plasma-derived Therapies Consumption Share by End-Users in 2027

    • Table South China Plasma-derived Therapies Consumption by Types from 2016 to 2027

    • Table South China Plasma-derived Therapies Consumption Share by Types from 2016 to 2027

    • Figure South China Plasma-derived Therapies Consumption Share by Types in 2016

    • Figure South China Plasma-derived Therapies Consumption Share by Types in 2021

    • Figure South China Plasma-derived Therapies Consumption Share by Types in 2027

    • Table South China Plasma-derived Therapies Consumption by End-Users from 2016 to 2027

    • Table South China Plasma-derived Therapies Consumption Share by End-Users from 2016 to 2027

    • Figure South China Plasma-derived Therapies Consumption Share by End-Users in 2016

    • Figure South China Plasma-derived Therapies Consumption Share by End-Users in 2021

    • Figure South China Plasma-derived Therapies Consumption Share by End-Users in 2027

    • Table East China Plasma-derived Therapies Consumption by Types from 2016 to 2027

    • Table East China Plasma-derived Therapies Consumption Share by Types from 2016 to 2027

    • Figure East China Plasma-derived Therapies Consumption Share by Types in 2016

    • Figure East China Plasma-derived Therapies Consumption Share by Types in 2021

    • Figure East China Plasma-derived Therapies Consumption Share by Types in 2027

    • Table East China Plasma-derived Therapies Consumption by End-Users from 2016 to 2027

    • Table East China Plasma-derived Therapies Consumption Share by End-Users from 2016 to 2027

    • Figure East China Plasma-derived Therapies Consumption Share by End-Users in 2016

    • Figure East China Plasma-derived Therapies Consumption Share by End-Users in 2021

    • Figure East China Plasma-derived Therapies Consumption Share by End-Users in 2027

    • Table Northeast China Plasma-derived Therapies Consumption by Types from 2016 to 2027

    • Table Northeast China Plasma-derived Therapies Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Plasma-derived Therapies Consumption Share by Types in 2016

    • Figure Northeast China Plasma-derived Therapies Consumption Share by Types in 2021

    • Figure Northeast China Plasma-derived Therapies Consumption Share by Types in 2027

    • Table Northeast China Plasma-derived Therapies Consumption by End-Users from 2016 to 2027

    • Table Northeast China Plasma-derived Therapies Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Plasma-derived Therapies Consumption Share by End-Users in 2016

    • Figure Northeast China Plasma-derived Therapies Consumption Share by End-Users in 2021

    • Figure Northeast China Plasma-derived Therapies Consumption Share by End-Users in 2027

    • Table Southwest China Plasma-derived Therapies Consumption by Types from 2016 to 2027

    • Table Southwest China Plasma-derived Therapies Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Plasma-derived Therapies Consumption Share by Types in 2016

    • Figure Southwest China Plasma-derived Therapies Consumption Share by Types in 2021

    • Figure Southwest China Plasma-derived Therapies Consumption Share by Types in 2027

    • Table Southwest China Plasma-derived Therapies Consumption by End-Users from 2016 to 2027

    • Table Southwest China Plasma-derived Therapies Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Plasma-derived Therapies Consumption Share by End-Users in 2016

    • Figure Southwest China Plasma-derived Therapies Consumption Share by End-Users in 2021

    • Figure Southwest China Plasma-derived Therapies Consumption Share by End-Users in 2027

    • Table Northwest China Plasma-derived Therapies Consumption by Types from 2016 to 2027

    • Table Northwest China Plasma-derived Therapies Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Plasma-derived Therapies Consumption Share by Types in 2016

    • Figure Northwest China Plasma-derived Therapies Consumption Share by Types in 2021

    • Figure Northwest China Plasma-derived Therapies Consumption Share by Types in 2027

    • Table Northwest China Plasma-derived Therapies Consumption by End-Users from 2016 to 2027

    • Table Northwest China Plasma-derived Therapies Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Plasma-derived Therapies Consumption Share by End-Users in 2016

    • Figure Northwest China Plasma-derived Therapies Consumption Share by End-Users in 2021

    • Figure Northwest China Plasma-derived Therapies Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Kedrion

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kedrion

    • Figure Sales and Growth Rate Analysis of Kedrion

    • Figure Revenue and Market Share Analysis of Kedrion

    • Table Product and Service Introduction of Kedrion

    • Table Company Profile and Development Status of Grifols

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Grifols

    • Figure Sales and Growth Rate Analysis of Grifols

    • Figure Revenue and Market Share Analysis of Grifols

    • Table Product and Service Introduction of Grifols

    • Table Company Profile and Development Status of Octaparma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Octaparma

    • Figure Sales and Growth Rate Analysis of Octaparma

    • Figure Revenue and Market Share Analysis of Octaparma

    • Table Product and Service Introduction of Octaparma

    • Table Company Profile and Development Status of CSL Behring LLC

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of CSL Behring LLC

    • Figure Sales and Growth Rate Analysis of CSL Behring LLC

    • Figure Revenue and Market Share Analysis of CSL Behring LLC

    • Table Product and Service Introduction of CSL Behring LLC

    • Table Company Profile and Development Status of Takeda

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda

    • Figure Sales and Growth Rate Analysis of Takeda

    • Figure Revenue and Market Share Analysis of Takeda

    • Table Product and Service Introduction of Takeda

    • Table Company Profile and Development Status of Bayer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer

    • Figure Sales and Growth Rate Analysis of Bayer

    • Figure Revenue and Market Share Analysis of Bayer

    • Table Product and Service Introduction of Bayer

    • Table Company Profile and Development Status of Shire

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shire

    • Figure Sales and Growth Rate Analysis of Shire

    • Figure Revenue and Market Share Analysis of Shire

    • Table Product and Service Introduction of Shire

    • Table Company Profile and Development Status of LFB

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of LFB

    • Figure Sales and Growth Rate Analysis of LFB

    • Figure Revenue and Market Share Analysis of LFB

    • Table Product and Service Introduction of LFB

    • Table Company Profile and Development Status of Bio Products Laboratory (BPL)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bio Products Laboratory (BPL)

    • Figure Sales and Growth Rate Analysis of Bio Products Laboratory (BPL)

    • Figure Revenue and Market Share Analysis of Bio Products Laboratory (BPL)

    • Table Product and Service Introduction of Bio Products Laboratory (BPL)

    • Table Company Profile and Development Status of Biotest

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biotest

    • Figure Sales and Growth Rate Analysis of Biotest

    • Figure Revenue and Market Share Analysis of Biotest

    • Table Product and Service Introduction of Biotest


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.